Tivic Health Systems Inc. announced its financial results for the third quarter and nine months ended September 30, 2025. The company reported continued progress in its strategic transformation and advancement of its biologics pipeline. During the quarter, Tivic completed the transfer of two Investigational New Drug (IND) applications from Statera Biopharma, enabling the company to conduct clinical trials in neutropenia and lymphocyte exhaustion, and to explore Entolimod's anti-tumor activity for potential cancer-related indications. The company also finalized cell line verification, a critical step to enable Current Good Manufacturing Practices (cGMP), required before filing a biologics license application (BLA) with the U.S. Food & Drug Administration. Tivic advanced the wind down of its consumer health technology business, discontinued significant resource allocation to ClearUP sales, and wrote off related inventory during the quarter. The company launched a new corporate website reflecting its updated mission and expanded clinical pipeline. Tivic further progressed discussions regarding potential deployment of Entolimod as a military countermeasure and stockpile drug, participating in the 2025 Military Health System Research Symposium. An audio replay of the company's conference call discussing these results will be available for 90 days on the Tivic Health website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102399) on November 14, 2025, and is solely responsible for the information contained therein.
Comments